Incyte Corporation
$ 99.98
-1.06%
25 Feb - close price
- Market Cap 20,110,414,000 USD
- Current Price $ 99.98
- High / Low $ 101.16 / 98.57
- Stock P/E 15.76
- Book Value 26.04
- EPS 6.41
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 0.30 %
- 52 Week High 112.29
- 52 Week Low 53.56
About
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Analyst Target Price
$107.09
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-10 | 2024-10-29 | 2024-07-30 | 2024-04-30 | 2024-02-13 | 2023-10-31 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 1.8 | 2.26 | 1.57 | 0.8 | 1.43 | 0.54 | -1.82 | 0.64 | 1.06 | 1.1 | 0.99 | 0.37 |
| Estimated EPS | 1.93 | 1.64 | 1.47 | 0.76 | 1.55 | 0.79 | -1.55 | 0.84 | 1.16 | 1.02 | 0.83 | 0.76 |
| Surprise | -0.13 | 0.62 | 0.1 | 0.04 | -0.12 | -0.25 | -0.27 | -0.2 | -0.1 | 0.08 | 0.16 | -0.39 |
| Surprise Percentage | -6.7358% | 37.8049% | 6.8027% | 5.2632% | -7.7419% | -31.6456% | -17.4194% | -23.8095% | -8.6207% | 7.8431% | 19.2771% | -51.3158% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INCY
2026-02-25 13:50:47
This article provides a technical analysis of Incyte Corporation (NASDAQ: INCY), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a strong risk-reward setup and offers real-time signal access and multi-timeframe signal analysis.
2026-02-24 22:50:34
Incyte (INCY) has seen a 36% share price gain over the past year, leading to a reassessment of its current valuation. While a Discounted Cash Flow (DCF) model suggests the stock is currently about 9.7% overvalued at US$100.85, its P/E ratio of 15.60x screens as undervalued compared to the biotech industry and a proprietary "Fair Ratio." The article presents bullish and bearish narratives, with fair values ranging from US$70 to US$135, highlighting the importance of individual assumptions regarding pipeline success and market conditions.
2026-02-24 03:52:30
Geron (GERN) has released its 2026 financial guidance, projecting RYTELO net product revenue of US$220 million to US$240 million and a reduction in operating expenses. The stock has seen a significant short-term price increase, but its long-term performance has been more challenging. Analysts currently estimate Geron's fair value at $3.33, suggesting it is undervalued, contingent on RYTELO's continued success and positive myelofibrosis trial data.
2026-02-23 20:59:41
Incyte Corporation is drawing investor attention with a 5.7% upside potential and strong revenue growth of 27.80%. Despite mixed valuation metrics and technical indicators, the company's robust product portfolio, promising R&D pipeline, and strategic partnerships suggest long-term value. Analysts have given the stock 12 buy ratings, 12 hold ratings, and 2 sell ratings, with an average target price of $107.09.
2026-02-23 19:28:37
Kymera Therapeutics (KYMR) shares surged 130% over the past year, outperforming the S&P 500, following a significant investment by Baker Bros. Advisors. The firm purchased over 2 million additional shares, valued at an estimated $135.45 million, boosting its immunology bet on Kymera. Kymera, a clinical-stage biotechnology company, is advancing its pipeline of targeted protein degradation therapies, with lead programs in immunology nearing key clinical readouts and a strong financial runway.
2026-02-23 13:40:00
Baker Bros. Advisors LP has significantly increased its stake in Kodiak Sciences (NASDAQ:KOD) by purchasing 2,608,696 shares, valued at an estimated $53.42 million. This investment comes as Kodiak Sciences' stock has surged 480% over the past year, far outperforming the S&P 500. The company, which specializes in therapies for retinal diseases, has several product candidates primarily for wet age-related macular degeneration and diabetic retinopathy advancing through Phase 3 trials.
